Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer
Ella Evron(Sidney Kimmel Comprehensive Cancer Center), Benjamin W. Corn(Shaare Zedek Medical Center), Ora Rosengarten(Sheba Medical Center), Georgeta Fried(Roche (Switzerland)), D. Matceyevsky(Tel Aviv Sourasky Medical Center), Abraham Kuten(Rambam Health Care Campus), Raphael Catane(Tel Aviv University), Moshe Inbar(Assuta Medical Center), Bella Kaufman(NYU Langone Health), David Geffen(Ben-Gurion University of the Negev), Myer Raphael Pfeffer(Assuta Medical Center), Tamar Karni(Assaf Harofeh Medical Center), H. Goldberg(Western Galilee Hospital), P. Chernobelsky(Soroka Medical Center), Roxolyana Abdah‐Bortnyak(Mansoura University), A. Ben-David(Tel Aviv University)
Cited by 56
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
|The Lancet|2002|1.7k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
|New England Journal of Medicine|1997|1.6k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k